Introduction
Nicotine is the main addictive component of cigarette smoke. During cigarette smoking, nicotine is readily absorbed and reaches the brain quickly. Nicotine binds with high affinity to nicotinic acetylcholine receptors in the ventral tegmental area, stimulating dopamine release in the nucleus accumbens, thereby effecting reward (Corrigall et al., 1992) .
Nicotine is metabolized rapidly in the liver, mainly via cytochrome P450-mediated Coxidation, yielding cotinine. The major P450 enzyme involved in nicotine metabolism in human liver is CYP2A6 (Hukkanen et al., 2005) , followed by CYP2B6 (Yamazaki et al., 1999) .
CYP2A6 genetic polymorphisms have been found to influence the metabolism of nicotine (Ray et al., 2009) . In mice, the role of CYP2A5 in nicotine clearance has been demonstrated (Siu and Tyndale, 2007; Zhou et al., 2010) . One or more of the mouse CYP2B enzymes may also be active toward nicotine (Siu and Tyndale, 2007) , though direct evidence for a role of mouse CYP2B in nicotine metabolism in vivo has yet to be obtained.
Previous works have led to the hypothesis that nicotine metabolism influences the risks of smoking-related lung carcinogenesis, as well as nicotine's pharmacological actions (Damaj et al., 2007; Wassenaar et al., 2011) . Presumably, a more rapid clearance of nicotine would make addicted smokers smoke more cigarettes per day, with consequently higher exposure to cigarette- JPET #208256 8 monitored in the Multiple Reaction Monitoring scan mode. To construct calibration curves, authentic nicotine and cotinine (0.05-5 ng for plasma and 0.5-500 ng for tissue) as well as 0.1 ng of cotinine-d 3 were added to 10 µl of blank mouse plasma or tissue homogenate, prior to extraction. The recovery of added standards was > 85% for plasma samples and >75% for tissue samples, at all concentrations tested.
In vitro Metabolism of Nicotine. The in vitro microsomal catalytic activity toward nicotine was determined in liver microsomes from 2-month-old WT, Cyp2a5-null and Cyp2a(4/5)bgs-null male mice. The post-microsomal supernatant fraction was used as cytosol.
Nicotine C-5'-oxidation assay was performed essentially as described previously (Zhou et al., 2010) . Reaction mixtures contained 1.0 or 10 µM nicotine, 0.5 mg/ml liver microsomal protein, and 1.0 mg/ml cytosolic protein, and the reactions were carried out at 37 o C in a final volume of 0.5 ml for 15 min. Cotinine formation was quantified by LC-MS/MS analysis, as described for the pharmacokinetics of plasma cotinine.
Nicotine-induced Pharmacological Effects. Two-month-old WT and Cyp2a(4/5)bgsnull male mice were given i.p. injection of saline or nicotine at 5.0 mg/kg, and they were tested for hypothermia response (body temperature) and antinociceptive response (two assays, tailimmersion and hot-plate tests). Groups of 8 animals were used for each treatment.
Body Temperature. Rectal temperature was measured by a thermister probe (inserted to 24 mm) and digital thermometer (Harvard Apparatus, Holliston, MA). Readings were taken before and (5, 15, 30, 45, 60, 120, 180 min) after the i.p. injection of either saline or nicotine.
The difference in rectal temperature before and after treatment was calculated for each mouse.
The ambient temperature in the laboratory varied form 22-24
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Tail-Immersion Test. Antinociception was assayed by the tail-immersion method (Sewell and Spencer, 1976) . In brief, mice were loosely restrained in a conical polypropylene tube. The tip (2-3 cm) of the tail was immersed in a 50 o C water bath and the latency of flick or removal of the tail from the water was recorded. At this temperature, the baseline latencies were approximately 1-3 s. On test day, each animal underwent two tail-immersion tests performed with a 1-min interval, for determination of the baseline latencies. The animals were then injected (i.p.) with saline or nicotine, and tested repeatedly at 5, 15, 30, 45, 60, 120, and 180 mice were injected intraperitoneally with either nicotine (the "drug" condition) or saline (the "non-drug" condition), and immediately placed in one of the two compartments for 20 min. Five hours later, the mice were injected with the alternate substance relative to its first injection (saline or nicotine), and immediately confined to the opposite chamber for 20 min. Mice stayed in their home cages between the two injections, or when not being tested in the CPP apparatus.
This procedure was repeated on Days 3 and 4, so that each animal received a total of three drug (nicotine) and three saline conditioning trials. Randomization was achieved at two levels: for each nicotine dose or mouse strain, the chamber that was paired with nicotine was randomly selected; for each mouse, the order in which the two differing conditions were presented within a day was also randomly selected. Mice injected with only saline in both side chambers were used as the control group. On the test day (Day 5), no injections were given. Animals were placed in the center compartment, and allowed access to all chambers for 15 min. Table 1 ).
The pharmacokinetic parameters for plasma nicotine in WT mice were comparable to what were previously reported (Zhou et al., 2010) . Compared to WT mice, the Cyp2a(4/5)bgs-null mice had ~ 93% decrease in CL/F values, accompanied by increases in AUC (13-fold), C max (7-fold), and t 1/2 (5-fold) values (Table 1) . Consistent with the decrease in nicotine metabolism, plasma levels of cotinine, the main circulating metabolite of nicotine, were much decreased in the Cyp2a(4/5)bgs-null mice, as indicated by decreases in AUC (4-fold) and C max (7.5-fold) values, compared to WT.
Levels of nicotine and cotinine were also determined for liver, the main metabolic organ, and brain, the target organ, and compared between WT and Cyp2a(4/5)bgs-null mice ( Fig. 2B and 2C). The concentration-time curves for nicotine or cotinine are similar in liver, brain, and plasma of either mouse strain. The AUC and C max values for brain or liver nicotine were both increased in Cyp2a(4/5)bgs-null mice over WT mice (by ~3-fold and ~1.5-fold, respectively), while the AUC and C max values for brain or liver cotinine were both decreased (by ~2-fold and ~6.5-fold, respectively) ( Table 1) .
We also determined the relative contributions of Cyp2a5 and the Cyp2b genes to nicotine clearance, by directly comparing nicotine and cotinine levels between male Cyp2a(4/5)bgs-null mice and male Cyp2a5-null mice ( Figure 3 and Table 2 ). Given that Cyp2s1 and Cyp2g1 are not expressed in hepatocytes, and Cyp2a4 is female predominant, the difference between male Cyp2a(4/5)bgs-null mice and male Cyp2a5-null mice is the presence of the five Cyp2b genes (2b9, 2b10, 2b13, 2b19, and 2b23) . In vitro studies of hepatic microsomal nicotine metabolism showed that rates of cotinine formation were not different between Cyp2a(4/5)bgs-null and Cyp2a5-null mice at a nicotine concentration of 1 µM (7.1 ± 0.8 vs 7.2 ± 1.3, respectively; mean ± S.D., n=3), but were ~60% lower in the Cyp2a(4/5)bgs-null than in Cyp2a5-null mice at a nicotine concentration of 10 µM (28.7 ± 0.7 vs 66.2 ± 2.3, respectively; mean ± S.D., n=3, P < 0.01), suggesting that the mouse CYP2B enzymes have higher K m values than CYP2A5 toward nicotine metabolism. In vivo studies of plasma nicotine and cotinine showed that, in the Cyp2a(4/5)bgs-null mice, there were further decreases (versus Cyp2a5-null) in nicotine clearance (~55% in CL/F values), and increases in AUC and C max (>65%), as well as t 1/2 (1.4-fold) values, and corresponding decreases in abundance of cotinine (by >40% in AUC and C max ) (Table 2) . Interestingly, the t 1/2 values were comparable between the two null strains. Thus, the mouse CYP2B enzymes also play a significant role in converting nicotine to cotinine in vivo, but they may not contribute to further clearance of cotinine.
Nicotine's Acute Pharmacological Effects on WT and Cyp2a(4/5)bgs-null mice.
Nicotine-induced acute pharmacological effects, including antinociception and hypothermia, were observed after i.p. injection of nicotine at 5.0 mg/kg to Cyp2a(4/5)bgs-null mice and WT mice. Mice were tested at various times (up to 180 min) after nicotine dosing, for rectal temperature ( Fig. 4A ) and for thermal nociceptive responses in tail-immersion ( place preference elicited at a nicotine dose of 0.5 mg/kg ( Fig. 5B and 5C ). As shown in Figure   5B , WT mice spent significantly more time in the nicotine-paired chamber after (day 5), than before (day 1), nicotine conditioning at 0.5 mg/kg (p < 0.05, either paired t-test or 2-way ANOVA, for day and chamber). There was no significant preference observed at other doses tested in WT mice (Fig. 5C ).
As predicted, the dose response in the Cyp2a(4/5)bgs-null mice shifted noticeably to the left, compared to that in WT mice, and a significant behavioral reinforcement response (place preference) was detected in Cyp2a(4/5)bgs-null, but not in WT, mice at a nicotine dose of 0.1 mg/kg (Fig. 5C) . Thus, the nicotine dose required to produce CPP in the Cyp2a(4/5)bgs-null mice was 4-fold lower than that in WT mice. Further analysis of the data in Figure 5C using twoway ANOVA (for treatment and genotype) indicated a significant effect of nicotine treatment (F = 5.38, P <0.01), but not genotype (F = 1.40, not significant), and a significant interaction between the two (F = 11.01, P < 0.01). In addition, paired t-test (data not shown) performed for each treatment group, comparing the number of transitions through the compartments between pre-condition (day 1) and after-condition (day 5), showed that there was no drug treatmentrelated difference, indicating that the treatments did not change animal mobility.
This article has not been copyedited and formatted. The final version may differ from this version. There are two commonly used models for assessing the rewarding properties of nicotine, the CPP test, in which animals are subjective to drug administration in order to elicit reward effects, and the self-administration test, which requires surgical implantation of a catheter, usually for intravenous drug administration, and an extensive operant training (Matta et al., 2007) . The CPP test offers several advantages over the self-administration model, including a simple methodology and well-established protocols (Cunningham et al., 2006; Grabus et al., 2006) ; however, the self-administration test, in which animals learn a task where the responses This article has not been copyedited and formatted. The final version may differ from this version. , 2006) , which suggested that novice subjects with slow nicotine metabolism are at a higher risk of becoming dependent on nicotine. However, it remains to be determined whether our results support the findings of a more recent study (Audrain-McGovern et al., 2007) , which suggested that normal nicotine metabolizers progressed more quickly to nicotine dependence than slow nicotine metabolizers, given that our study was not designed to test how quickly nicotine dependence was established in Cyp2a(4/5)bgs-null and WT mice. Additionally, our study does not address the relationship between rates of nicotine metabolism and amounts of cigarette smoking (i.e., nicotine intake) in subjects that are already dependent on nicotine. The latter relationship, which could be studied using the Cyp2a(4/5)bgs-null mouse and the nicotine self-administration model, is already strongly supported by data from human studies (Amos et al., 2010) . Notably, these mouse model can be used to study the role of brain CYP2B in the metabolism of a variety of centrally acting drugs or neurochemicals, in addition to nicotine, such as bupropion, ecstasy, and serotonin (Ekins et al., 2008) .
In summary, we proved that CYP2B enzymes, as well as CYP2A5, play significant roles in nicotine metabolism in vitro and in nicotine clearance in vivo. We further showed that the decrease in nicotine clearance, resulting from genetic ablation of the major nicotine-metabolizing P450 enzymes, in the Cyp2a(4/5)bgs-null mouse led to increased sensitivity to nicotine's pharmacological effects and nicotine-induced acute reward actions in the CPP test. Our findings support the notion that decreases in nicotine clearance (e.g., as a result of CYP genetic polymorphism) will not only affect nicotine's pharmacological actions, but will also likely modify smoking behavior in humans. Nonetheless, additional studies using the Cyp2a(4/5)bgsnull mouse model, including nicotine self-administration tests and analysis of nicotine metabolism in the brain, are required, in order to provide a definitive understanding of how pharmacokinetic parameters may alter nicotine's rewarding effects.
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